Published in J Cardiovasc Pharmacol on July 01, 1989
Comparison of the effects of the novel vasodilator FK409 with those of nitroglycerin in isolated coronary artery of the dog. Br J Pharmacol (1991) 0.91
Update on nitrate tolerance. Br J Clin Pharmacol (1992) 0.77
Baroreflex resetting but no vascular tolerance in response to transdermal glyceryl trinitrate in conscious rabbits. Br J Pharmacol (1996) 0.75
Effects of N-acetylcysteine on nitroglycerin-induced relaxation and protein phosphorylation of porcine coronary arteries. Heart Vessels (1998) 0.75
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med (1998) 2.65
Effects of home-based intervention on unplanned readmissions and out-of-hospital deaths. J Am Geriatr Soc (1998) 2.49
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation (2000) 2.49
Heart failure in older people: the epidemic we had to have. Med J Aust (2001) 2.03
Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg (1995) 1.75
Is informed consent to clinical trials an "upside selective" process in acute coronary syndromes? Am Heart J (2000) 1.74
Pharmacokinetics of the H2- receptor antagonist ranitidine in man. Br J Clin Pharmacol (1981) 1.67
N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation (1995) 1.58
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J (2000) 1.55
Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology (1985) 1.54
Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation (2000) 1.53
Nitrate resistance in platelets from patients with stable angina pectoris. Circulation (1999) 1.49
Utility of a weight-based heparin nomogram for patients with acute coronary syndromes. Intern Med J (2003) 1.46
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J (2001) 1.46
High-pressure liquid chromatographic determination of ranitidine, a new H2-receptor antagonist, in plasma and urine. J Pharm Sci (1980) 1.46
Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur Heart J (2002) 1.44
Acute myocardial uptake of digoxin in humans: correlation with hemodynamic and electrocardiographic effects. J Am Coll Cardiol (1990) 1.41
Pharmaceutical Benefits Scheme (PBS) Med J Aust (1994) 1.39
Influence of food on the bioavailability of a sustained-release verapamil preparation. J Pharm Sci (1990) 1.38
The use of prindolol (Visken) in the treatment of hypertension. Med J Aust (1972) 1.38
Beta-adrenergic receptor blocking drugs, hypertension and plasma renin. Br J Clin Pharmacol (1975) 1.34
Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med (1999) 1.33
Calcium antagonists: a new class of drugs. Pharmacol Ther (1983) 1.28
The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy. Br J Clin Pharmacol (1986) 1.28
Impact of a toxicology service on a metropolitan teaching hospital. Emerg Med (Fremantle) (2001) 1.27
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost (2010) 1.25
Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations. Lancet (1980) 1.24
A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. Br J Clin Pharmacol (1979) 1.23
Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol (1996) 1.22
Plasma norepinephrine levels in essential hyoertension. N Engl J Med (1973) 1.20
Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers. Br Med J (Clin Res Ed) (1985) 1.15
Double-blind controlled trial of ranitidine versus cimetidine in the treatment of duodenal ulceration. Aust N Z J Med (1982) 1.14
Methyldopa and haemolytic anaemia. Med J Aust (1967) 1.13
High dose of antacid (Mylanta II) reduces bioavailability of ranitidine. Br Med J (Clin Res Ed) (1982) 1.13
Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. Br J Clin Pharmacol (1979) 1.10
Evaluation of indapamide in the treatment of hypertension. J Cardiovasc Pharmacol (1980) 1.10
Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics. Int J Cardiol (1986) 1.10
Measurement of carbamazepine and its epoxide metabolite by high-performance liquid chromatography, and a comparison of assay techniques for the analysis of carbamazepine. Clin Chem (1977) 1.07
Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation (1983) 1.07
Computerized neuropsychological tests in the early detection of dementia: prospective findings. J Int Neuropsychol Soc (1997) 1.06
Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension. Aust N Z J Med (1978) 1.04
Risk factors for cardiovascular disease in chronic spinal cord injury patients. Paraplegia (1992) 1.04
Blood-brain barrier disruption using mannitol: time course and electron microscopy studies. Am J Physiol (1989) 1.03
Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet (1978) 1.03
Ocular side effects with 5-fluorouracil. Aust N Z J Med (1979) 1.02
A comparison of chlorothiazide, chlorthalidone and cyclopenthiazide in the treatment of hypertension. Med J Aust (1973) 1.02
Peripherally inserted central catheters revisited. Am J Surg (1998) 1.01
How safe are beta-blocking drugs? Med J Aust (1977) 1.01
Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease. Circulation (1983) 1.01
Effects of sodium intake on inherited hypertension in the rat. Lancet (1971) 1.00
Computerized delayed matching to sample and paired associate performance in the early detection of dementia. Appl Neuropsychol (1995) 1.00
Nitroglycerin-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade. J Pharmacol Exp Ther (1989) 0.99
Plasma dopamine -hydroxylase and noradrenaline amounts in essential hypertension. Clin Sci (1973) 0.99
S-nitrosothiols as vasodilators: implications regarding tolerance to nitric oxide-containing vasodilators. Br J Pharmacol (1989) 0.98
The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels. Clin Exp Pharmacol Physiol (1975) 0.96
The relationship between the vascular responses to the peptides ranatensin and angiotensin. Eur J Pharmacol (1971) 0.94
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med (2001) 0.94
High-performance liquid chromatographic analysis of captopril in plasma. J Pharm Sci (1981) 0.94
Inheritance of high blood-pressure in the spontaneously hypertnsive rat. Lancet (1969) 0.94
Plasma renin levels and vascular complications in hypertension. Br Med J (1973) 0.94
The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function. Eur J Clin Pharmacol (1987) 0.93
A study of the alpha-1 adrenoceptor blocker prazosin in the prophylactic management of autonomic dysreflexia in high spinal cord injury patients. Clin Auton Res (1992) 0.93
Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines. Prostate (2008) 0.92
Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin. J Cardiovasc Pharmacol (1987) 0.92
Antibiotic-induced release of endotoxin in chronically bacteriuric patients. Antimicrob Agents Chemother (1991) 0.92
Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine. J Chromatogr (1983) 0.92
Antihypertensive and noradrenaline-depleting effects of alpha-methyl-5-hydroxytryptophan in the rat. Eur J Pharmacol (1969) 0.92
Quantitative Limulus lysate assay for endotoxin and the effect of plasma. J Clin Pathol (1991) 0.92
Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Ther Drug Monit (1996) 0.92
Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris. Circulation (1988) 0.91
Synthesis and turnover of norepinephrine in the heart of the spontaneously hypertensive rat. Circ Res (1969) 0.91
Pharmacokinetic properties of captopril after acute and chronic administration to hypertensive subjects. Am J Cardiol (1982) 0.91
Positive chronotropic responses produced by alpha-adrenoreceptors in the pithed rat. J Auton Pharmacol (1982) 0.91
Amelioration of renal ischaemia-reperfusion injury by liposomal delivery of curcumin to renal tubular epithelial and antigen-presenting cells. Br J Pharmacol (2012) 0.91
Prevention and reversal of tolerance to nitroglycerine with N-acetylcysteine. J Cardiovasc Pharmacol (1985) 0.90
Drugs and impaired male sexual function. Drugs (1979) 0.90
Secretion of dopa in phaeochromocytoma. Br Med J (1972) 0.90
The effects of varying doses of angiotensin on renal function and blood pressure in man and dogs. Clin Sci (1965) 0.89
Cardiovascular effects of dopamine in the anaesthetized dog. Clin Exp Pharmacol Physiol (1975) 0.89
The effect of penicillamine and related thiols on cyclophosphamide-induced cystitis and bone marrow suppression. Int J Tissue React (1984) 0.89
Pharmacokinetic and gastric secretory studies of ranitidine in man. Scand J Gastroenterol Suppl (1981) 0.89
Neovascular complications associated with rubeosis iridis and peripheral retinal detachment after retinal detachment surgery. Am J Ophthalmol (1998) 0.89
Renal-clip hypertension in rabbits immunised against angiotensin II. Lancet (1970) 0.89
Aortic sclerosis: not an innocent murmur but a marker of increased cardiovascular risk. Heart (2005) 0.89
Renal-clip hypertension in rabbits immunized against angiotensin II. Circ Res (1970) 0.89
High-performance liquid chromatographic assay of perhexiline maleate in plasma. J Pharm Sci (1981) 0.89
An unusual case of intrathoracic phaeochromocytoma. Aust N Z J Surg (1974) 0.88
Primary pulmonary hypertension and anorectic drugs. N Engl J Med (1999) 0.88
Failure of psychosocial stress to induce chronic hypertension in the rat. J Hypertens (1984) 0.88
Pharmacokinetics of prazosin in normotensive subjects after low oral doses. Clin Pharmacokinet (1981) 0.88
Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol (2000) 0.88
The characteristics of [3H]-clonidine binding to an alpha-adrenoceptor in membranes from guinea-pig kidney. Br J Pharmacol (1979) 0.87
Methicillin-resistant Staphylococcus aureus in an Australian teaching hospital. J Hosp Infect (1984) 0.87